Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scan grading predicts growth problems in child tumor survivors

NCT ID NCT07342686

Knowledge-focused Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 500 children who had surgery for a rare brain tumor called craniopharyngioma. Researchers used MRI scans to grade how much the tumor damaged a key brain area (the hypothalamus). They found that more damage was linked to higher rates of growth hormone deficiency and thinking or emotional problems. The goal is to help doctors create better care plans for each child based on their individual risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help doctors predict which children need closer monitoring for growth and brain health after brain tumor surgery.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all patients or hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

500 people

The number who actually took part.

Started

Dec 2023

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

\*\*Study Population Description\*\* Children and adolescents ≤ 18 years of age who underwent primary surgical resection for craniopharyngioma at one of six tertiary pediatric centers in China between January 2013 and December 2023, had complete pre- and post-operative brain MRI, endocrine, and neuropsychological data, and were followed for ≥ 2 years without tumor re-operation.

Ages

Up to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≤18 years at the time of craniopharyngioma resection; * Pathologically confirmed craniopharyngioma; * Postoperative follow-up duration ≥2 years; * Complete preoperative and postoperative MRI data, endocrine test results, neuropsychological assessment records, and nursing documentation; * No preoperative GHD, neuropsychological disorders, or other systemic diseases affecting growth or neurodevelopment. Exclusion Criteria: * Preoperative diagnosis of GHD, cognitive impairment, or emotional disorders; * Concurrent intracranial tumors or systemic diseases (e.g., congenital growth hormone deficiency, Down syndrome); * Loss to follow-up or incomplete clinical data; * Tumor recurrence requiring reoperation during follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Craniopharyngioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

craniopharyngioma isolated congenital growth hormone deficiency pituitary dwarfism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Craniopharyngioma Growth hormone deficiency (GHD)

Contacts and locations

Locations

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.